CT Man’s Early Alzheimer’s Diagnosis Sparks Hope with Breakthrough Drug

UPDATE: A Connecticut man’s urgent pursuit for answers led to a groundbreaking Alzheimer’s diagnosis and a promising treatment option. Lee Ross, 61, was diagnosed with early onset Alzheimer’s disease after struggling with memory issues for years. This development comes as researchers unveil significant advancements in the fight against the disease.

Ross, a married father of two adult sons, began noticing troubling cognitive changes that prompted him to seek medical help. “Given my background, I had been noticing for a couple of years that I could not remember things like I used to,” Ross shared. Despite being told it could be due to anxiety or lack of sleep, he persisted until he received confirmation of his diagnosis earlier this year.

“I just knew that something wasn’t right,” he recalled, emphasizing the importance of early detection in managing Alzheimer’s. The disease is characterized by the accumulation of amyloid plaque in the brain, which disrupts neural connections and cognitive function.

Ross was forced to retire from his role as legislative director for Connecticut’s judicial branch, a job that heavily relied on memory and reasoning abilities. “All of a sudden, I am an Alzheimer’s patient,” he stated, reflecting on his emotional journey following the diagnosis.

However, hope emerged when Ross learned about Leqembi, a new drug developed by Eisai in collaboration with Biogen. This medication is designed to slow the progression of Alzheimer’s by reducing amyloid buildup in the brain, and it has been shown to change the course of the disease.

“I didn’t hesitate for a second,” Ross said of his decision to start the treatment. “The benefits of this far outweigh the risks.”

The Alzheimer’s Association reported that there are currently about 80,000 people living with Alzheimer’s in Connecticut, along with twice as many caregivers. Nationwide, approximately 250,000 people are affected by younger onset Alzheimer’s, defined as diagnoses occurring before the age of 65.

Kristen Cusato, director of communications for the Alzheimer’s Association Connecticut-Rhode Island Chapter, highlighted the significance of Leqembi, stating it creates “a whole new world to treat patients.” The treatment allows for earlier intervention, giving families more time together and potentially altering the trajectory of the disease.

Despite facing side effects, including temporary brain swelling, Ross expressed a commitment to continue the treatment, underscoring that “the alternative is just not an option.” He has since become an advocate for early testing and treatment, encouraging others to seek help.

“Take charge of your own brain health,” Cusato urged, noting the importance of education and awareness surrounding Alzheimer’s.

As part of his advocacy efforts, Ross has organized a team for the upcoming Walk to End Alzheimer’s in Greater Hartford, scheduled for October 19, 2023, at Rentschler Field. The event, which opens at 9 a.m. with a ceremonial Promise Garden at 10 a.m., aims to raise awareness and funds for Alzheimer’s research.

Ross’s journey serves as a powerful reminder of the critical need for early diagnosis and treatment options. “If I could do something, if I could maybe tell my story a bit, maybe they would think ‘I should get some testing,’” he said. His hope is that by sharing his experience, others will feel empowered to take control of their health.

For those seeking information about Alzheimer’s or to speak with a professional, the Alzheimer’s Association offers a 24/7 helpline at 1-800-272-3900 or visit alz.org/ct.